© Munich Re

Longevity and Aging: A New Approach Using Metformin

May 2020

In 1900, U.S. life expectancy for men and women was approximately 47 years.1 A person born in 2018 was expected to live nearly 79 years, an increase of one-tenth of a year from 2017.2 Various factors contributed to this increase and some scientists believe aging could be delayed to improve the quality of life in old age.

An online poll conducted among 3,222 adults ages 18 and older in the United States revealed that while most people do want to live longer than their average life expectancy, it is predicated on their quality of life, such as how much pain they would experience or whether they would be able to live independently.3 Retirees also have concerns about their ability to afford the expenses that come with living longer, as traditional retirement planning models were based on a shorter life span.4

What if the quality of life could be improved and the effects of aging could be postponed?

S. Jay Olshansky, PhD, an epidemiologist at the University of Illinois at Chicago School of Public Health, believes the upper limits to human longevity can be achieved through scientific means that intervene in the aging process.5 If the cause of aging is found, health in older age could be improved. Although there have been advances in medicine, living longer has not necessarily coincided with an improvement in the quality of life.

Olshansky introduced the Longevity Dividend initiative to promote research that focuses on slow aging to extend a healthy lifespan and combatting the diseases of old age.5 He believes the potential benefits from advances in aging science have been underestimated by most scientists. Presently, scientists and physicians focus on the treatment for diseases to extend life.

How can medical advancements extend a healthy lifespan and combat the diseases of old age?

Medical Intervention to Slow Aging

Dr. Nir Barzilai, Director of the Institute for Aging Research at Albert Einstein College of Medicine, and a group of researchers from the American Federation for Aging Research (AFAR) are working to validate metformin as the first-ever anti-aging medication.6 Metformin is a widely-used antidiabetic treatment that has also been shown to increase the production of known longevity-promoting signaling molecules in cells.6 This drug favorably influences biological outcomes that are associated with the development of age-related conditions including inflammation, oxidation, diminished autophagy and cellular senescence.7 Autophagy is the natural, destructive mechanism that disassembles unnecessary or dysfunctional components. It allows the orderly degradation and recycling of cellular components.

Dr. Nir said, “We would rather prevent aging, and by that, prevent the onset of multiple diseases.”8 Craig Currey, a lead researcher at Cardiff University, also found that metformin already demonstrated positive results in treating cancer and cardiovascular diseases in addition to treating diabetes.8 Metformin helps control diabetes by increasing insulin sensitivity and decreasing production of glucose in the liver.9 Metformin also benefits cells in the human body by increasing oxygen molecules released into a cell.8  Non-human studies demonstrated metformin’s ability to slow the aging process in mammals; thus, it is hoped the same can be demonstrated in humans.7,8

A groundbreaking study approved by the Food and Drug Administration (FDA) called Targeting Aging with Metformin (TAME) aims to evaluate metformin’s ability to slow aging. The clinical trials will include 3,000 people, who either suffer from or have a high risk of developing diseases, tracked over a course of six years – where half of the participants will receive metformin, and the other half will receive a placebo.6 Success of the study will be determined by whether the drug slows down the onset of major age-related chronic diseases – such as cardiovascular disease, cancer and dementia.6 Additionally, metformin helps the body repair DNA, which is critical in cancer prevention.

Longevity-signaling molecules in human cells, known as mTOR and AMPK, are increased when taking metformin – which helps to reduce fat and sugar storage that support the cells function youthfully, and prevent the early stages in atherosclerosis development (hardening of the arteries).6 Treatment with metformin can activate AMPK by cleaning up proteins in the brain that can cause brain cells to die.6 Build-up of brain proteins can cause brain cell death and abnormality in neuro-degenerative diseases. These affects have been demonstrated in animal and laboratory studies. As humans age, AMPK activity decreases which can make the body more susceptible to disease.6,9

Underwriting Impact

Although further research is needed to validate the specific impact of metformin on the human body, scientists and physicians hope additional studies will provide further insight and understanding into how this medication could positively impact longevity. Underwriters in all lines of business should be aware of how treatment with the drug may impact mortality and potentially improve the quality of life in old age for patients across the United States.

Contact the Author
Lynn Bernstein
Lynn Bernstein, BSN, FALU, FLMI
Senior Underwriting Consultant
Underwriting Services
1Life expectancy at birth, at 65 years of age, and at 75 years of age, by race and sex: United States, selected years 1900–2007 (2010) Centers for Disease Control and Prevention. cdc.gov pdf https://www.cdc.gov/nchs/data/hus/2010/022.pdf 2Adamy, J. (2020, January 30). Life Expectancy Rises in U.S. for First Time in Four Years. The Wall Street Journal. https://www.wsj.com/articles/life-expectancy-rises-in-u-s-for-first-time-in-four-years-11580398277 3Poll: How many people want to live to 100. (2019, May 9). Axios. https://www.axios.com/poll-live-to-100-years-old-d7f54075-e6ac-448e-837a-eb6e28117cce.html 4Singleterry, M. (2018, April 9). Your long life could be the death of your retirement savings. The Washington Post. https://www.washingtonpost.com/news/get-there/wp/2018/04/09/your-long-life-could-be-the-death-of-your-retirement-savings/ 5Olshansky, S. J. (2016, January 8). Articulating the Case for the Longevity Dividend. Cold Spring Harbor Perspectives in Medicine. Cold Spring Harbor Perspectives in Medicine. www.perspectivesinmedicine.cshlp.org/content/6/2/a025940.long 6Linton, R. (2017, April). Will metformin become the first anti-aging drug? Life Extension Magazine. https://www.lifeextension.com/magazine/2017/4/metformin-slashes-cancer-risks 7Barzilai, N., et al. (2018, May 10). Metformin as a Tool to Target Aging. US National Library of Medicine / National Institutes of Health. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943638/ 8(2016, February 5). Metformin may promote anti-aging.Worldhealth.net blog. https://worldhealth.net/news/metformin-may-promote-anti-aging/ 9Peyer, J. (2017, January 27). TAME: Teaching old diabetes drugs new tricks. Geroscience. http://geroscience.com/diabetes-drugs/  

Rechtlicher Hinweis

Die gewünschte Information bezieht sich auf Finanzinstrumente, Wertpapiere oder diesbezügliche Angebote, die nicht in oder in die Vereinigten Staaten, Kanada, Australien oder Japan und von US-Bürgern (gemäß der Definition in der Regulation S des US Securities Act 1933) angeboten werden, noch in und von diesen Ländern bzw. US-Bürgern akzeptiert werden dürfen. Folglich wurden diese Finanzinstrumente oder Wertpapiere sowie diesbezügliche Angebote (i) weder nach dem Amerikanischen Wertpapiergesetz noch nach einem Gesetz eines US-Bundesstaates registriert; (ii) diese Finanzinstrumente oder Wertpapiere dürfen nicht direkt oder indirekt in oder in die Vereinigten Staaten angeboten, verkauft, wiederverkauft, verpfändet oder geliefert werden, es sei denn, es liegt eine Befreiung von den Registrierungsanforderungen des Amerikanischen Wertpapiergesetzes vor; und (iii) solche Finanzinstrumente oder Wertpapiere können dem US-Steuerrecht unterliegen. Keine der hierin enthaltenen Unterlagen begründet ein Verkaufsangebot oder eine Aufforderung eines Angebots zum Kauf von Finanzinstrumenten oder Wertpapieren in den Vereinigten Staaten, Kanada, Australien oder Japan bzw. an US-Bürger oder in eine andere Rechtsordnung, in der ein solches Angebot oder dessen Einholung rechtswidrig ist. Personen, die ein Angebot annehmen möchten, dürfen weder die Post der Vereinigten Staaten, Kanadas, Australiens oder Japans oder irgendein Mittel oder Instrument (wie z.B. Faxübertragung, Telex oder Telefon) des Zwischenstaatlichen- oder Außenhandels, noch irgendwelche Einrichtungen einer inländischen Wertpapierbörse der Vereinigten Staaten, Kanadas, Australiens oder Japans für irgendeinen Zweck benutzen, der direkt oder indirekt mit der Annahme eines Angebots zusammenhängt. Annahmen oder andere sich auf ein Angebot beziehende Unterlagen dürfen nicht postalisch in den Vereinigten Staaten, Kanada, Australien oder Japan frankiert oder abgestempelt werden. Alle Personen, die ein Angebot annehmen möchten, müssen eine Adresse außerhalb der USA, Kanada, Japan und Australien für den Erhalt jeglicher Finanzinstrumente oder Wertpapiere angeben. Darüber hinaus wird von jedem Inhaber der relevanten Finanzinstrumente oder Wertpapieren angenommen, dem Emittenten dargelegt zu haben, dass (i) er kein US-Bürger ist und (ii) dass er diese Finanzinstrumente oder Wertpapiere nicht auf Rechnung eines US-Bürgers erwirbt.

Weder die in diesen Seiten enthaltenen Informationen, noch irgendeine Meinungsäußerung begründen ein Angebot oder eine Aufforderung, Finanzinstrumente oder Wertpapiere in irgendeiner Rechtsordnung zu erwerben. Jegliches Angebot oder jegliche Aufforderung wird nur in Unterlagen gemacht, die dafür rechtzeitig veröffentlicht werden; und jegliches Angebot und jegliche Aufforderung ist beschränkt auf die in diesen Unterlagen bereitgestellten Informationen.

Please scroll and read to the very bottom, before you can confirm.